Market closedNon-fractional
Omeros/OMER
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Omeros
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Ticker
OMER
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Seattle, United States
Employees
198
Website
www.omeros.com
Omeros Metrics
BasicAdvanced
$306M
Market cap
-
P/E ratio
-$1.96
EPS
1.36
Beta
-
Dividend rate
Price and volume
Market cap
$306M
Beta
1.36
Financial strength
Current ratio
4.757
Quick ratio
4.03
Long term debt to equity
-627.63
Total debt to equity
-661.939
Interest coverage (TTM)
-5.39%
Management effectiveness
Return on assets (TTM)
-21.03%
Return on equity (TTM)
2,185.05%
Valuation
Price to book
-4.29
Price to tangible book (TTM)
-4.29
Price to free cash flow (TTM)
-2.294
Growth
Earnings per share change (TTM)
-363.92%
3-year earnings per share growth (CAGR)
-6.96%
What the Analysts think about Omeros
Analyst Ratings
Majority rating from 3 analysts.
Omeros Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$37M
312.22%
Profit margin
0.00%
NaN%
Omeros Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.59
-$0.60
-$0.15
-$0.63
-
Expected
-$0.57
-$0.62
-$0.56
-$0.58
-$0.70
Surprise
3.75%
-2.49%
-72.97%
8.50%
-
Omeros News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Omeros stock?
Omeros (OMER) has a market cap of $306M as of July 27, 2024.
What is the P/E ratio for Omeros stock?
The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of July 27, 2024.
Does Omeros stock pay dividends?
No, Omeros (OMER) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Omeros dividend payment date?
Omeros (OMER) stock does not pay dividends to its shareholders.
What is the beta indicator for Omeros?
Omeros (OMER) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Omeros stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.